Meeting Banner
Abstract #2722

Breast Tumor Metabolic Imaging Biomarker kio Correlates with Histopathology Residual Cancer Measures

Charles S. Springer, Jr.1,2, Xin Li1, Alina Tudorica3, Karen Y. Oh3, Stephen Y-C. Chui2,4, Nicole Roy3, Megan L. Troxell2,5, Arpana Naik2,6, Kathleen A. Kemmer4, Yiyi Chen2,7, Megan L. Holtorf2, Aneela Afzal1, and Wei Huang1,2

1Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, United States, 2Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States, 3Diagnostic Radiology, Oregon Health & Science University, Portland, OR, United States, 4Medical Oncology, Oregon Health & Science University, Portland, OR, United States, 5Pathology, Oregon Health & Science University, Portland, OR, United States, 6Surgical Oncology, Oregon Health & Science University, Portland, OR, United States, 7Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, United States

The new DCE-MRI biomarker kio measures on-going vital metabolic activity. Whole breast tumor kio correlates well with pathology determinations of residual cancer burden and tumor invasive cell volume fraction from surgical specimens obtained just a few days later.

This abstract and the presentation materials are available to members only; a login is required.

Join Here